Compare Bristol-Myers Squibb Co (BMY) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Jones Lang LaSalle Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.64 (market cap $129.94B), while Jones Lang LaSalle Inc trades at $362.61 (market cap $16.72B). The key difference: Bristol-Myers Squibb Co is far larger — about 7.8× Jones Lang LaSalle Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| BMY | JLL | |
|---|---|---|
Market Cap | $129.94B | $16.72B |
Sector | Health | Real Estate |
52-Week High | $65.89 | $373.24 |
52-Week Low | $42.60 | $280.16 |
Enterprise Value | $163.92B | $19.48B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
JLL trades at $363.49, up 1.72% today, near its 52-week high. The stock exhibits bullish technical signals with a golden cross and strong momentum, supported by consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income margin improving to 3.64%. Analyst consensus is bullish with a $391.50 price target, and institutional holdings show confidence from firms like Bank of America.
Outlook remains positive driven by earnings growth and operational strength, but risks include economic sensitivity and competitive pressures. The stock offers upside to consensus targets, though valuation metrics like P/E of 17.43 require monitoring for sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
